Patents Assigned to Cellerant Therapeutics, Inc.
  • Humanized anti-CLL-1 antibodies
    Patent number: 11072662
    Abstract: Provided herein are humanized antibodies specific for CLL-1.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: July 27, 2021
    Assignee: Cellerant Therapeutics, Inc.
    Inventors: Ying-Ping Jiang, Jagath R. Junutula, Leonard G. Presta, Naoya Tsurushita
  • Isoquinolidinobenzodiazepines
    Patent number: 10898580
    Abstract: This disclosure provides novel isoquinolidinobenzodiazepines. These compounds can also be incorporated into antibody-drug conjugates.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: January 26, 2021
    Assignee: Cellerant Therapeutics, Inc.
    Inventors: Jagath R. Junutula, Vasu Jammalamadaka
  • Antibodies specific for CLL-1
    Patent number: 10723805
    Abstract: Provided herein are antibodies specific for CLL-1.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: July 28, 2020
    Assignee: Cellerant Therapeutics, Inc.
    Inventors: Ping Jiang, Holger Karsunky, Rob Tressler
  • ANTI-IL1-RAP ANTIBODIES
    Publication number: 20190338038
    Abstract: Provided herein are antibodies specific for IL1-RAP.
    Type: Application
    Filed: October 16, 2017
    Publication date: November 7, 2019
    Applicant: Cellerant Therapeutics, Inc.
    Inventors: Ying Ping Jiang, Jagath R. Junutula, Leonard G. Presta
  • METHODS OF EXPANDING MYELOID CELL POPULATIONS AND USES THEREOF
    Publication number: 20190241872
    Abstract: The present disclosure relates to a method of expanding myeloid progenitor cells by culturing an initial population of cells in a medium comprising a mixture of cytokines and growth factors that promote growth and expansion of the myeloid progenitor cells. The expanded cell population provides a source of cells as therapeutic treatments for neutropenia and/or thrombocytopenia arising in patients subjected to myeloablative therapy and hematopoietic stem cell transplantation.
    Type: Application
    Filed: February 11, 2019
    Publication date: August 8, 2019
    Applicant: CELLERANT THERAPEUTICS, INC.
    Inventors: TIMOTHY C. FONG, ADRIANUS GEERTRUDIS WILHELMUS DOMEN, JULIE LYNNE CHRISTENSEN
  • Isoquinolidinobenzodiazepine (IQB)-1(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimers
    Patent number: 10350218
    Abstract: Provided herein are isoquinolidinobenzodiazepine (IQB)-1(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimers, antibody-drug conjugates comprising them and methods of use for killing cells and treating disease.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: July 16, 2019
    Assignee: Cellerant Therapeutics, Inc.
    Inventors: Jagath R. Junutula, Sean W. Smith, Dmitry Borkin, Sylvia Degrado, Sanjeevani Ghone
  • Antibodies that specifically bind to TIM3
    Patent number: 10301394
    Abstract: Provided herein are antibodies specific for TIM3 that can be used to detect cancer cells, in particular, cancer stem cells. The antibodies can also be used in therapeutic compositions for treating cancer and reducing inflammation.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: May 28, 2019
    Assignee: Cellerant Therapeutics, Inc.
    Inventors: Holger Karsunky, Ying-Ping Jiang
  • Methods of expanding myeloid cell populations and uses thereof
    Patent number: 10260044
    Abstract: The present disclosure relates to a method of expanding myeloid progenitor cells by culturing an initial population of cells in a medium comprising a mixture of cytokines and growth factors that promote growth and expansion of the myeloid progenitor cells. The expanded cell population provides a source of cells as therapeutic treatments for neutropenia and/or thrombocytopenia arising in patients subjected to myeloablative therapy and hematopoietic stem cell transplantation.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: April 16, 2019
    Assignee: CELLERANT THERAPEUTIC, INC.
    Inventors: Timothy C. Fong, Adrianus Geertrudis Wilhelmus Domen, Julie Lynne Christensen
  • HUMANIZED ANTI-CLL-1 ANTIBODIES
    Publication number: 20180355044
    Abstract: Provided herein are humanized antibodies specific for CLL-1.
    Type: Application
    Filed: November 22, 2016
    Publication date: December 13, 2018
    Applicant: Cellerant Therapeutics, Inc.
    Inventors: Ying-Ping Jiang, Jagath R. Junutula, Leonard G. Presta, Naoya Tsurushita
  • Isoquinolidinobenzodiazepines
    Patent number: 9974864
    Abstract: This disclosure provides novel isoquinolidinobenzodiazepines. These compounds can also be incorporated into antibody-drug conjugates.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: May 22, 2018
    Assignee: Cellerant Therapeutics, Inc.
    Inventors: Jagath R. Junutula, Vasu Jammalamadaka
  • Antibodies specific for CLL-1
    Patent number: 9850314
    Abstract: Provided herein are antibodies specific for CLL-1.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: December 26, 2017
    Assignee: Cellerant Therapeutics, Inc.
    Inventors: Ping Jiang, Holger Karsunky, Rob Tressler
  • Antibodies that specifically bind to TIM3
    Patent number: 9631026
    Abstract: Provided herein are antibodies specific for TIM3 that can be used to detect cancer cells, in particular, cancer stem cells. The antibodies can also be used in therapeutic compositions for treating cancer and reducing inflammation.
    Type: Grant
    Filed: August 12, 2014
    Date of Patent: April 25, 2017
    Assignee: Cellerant Therapeutics, Inc.
    Inventors: Holger Karsunky, Ying-Ping Jiang
  • Isoquinolidinobenzodiazepines
    Patent number: 9504694
    Abstract: This disclosure provides novel isoquinolidinobenzodiazepines. These compounds can also be incorporated into antibody-drug conjugates.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: November 29, 2016
    Assignee: Cellerant Therapeutics, Inc.
    Inventors: Jagath R. Junutula, Vasu Jammalamadaka
  • Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof
    Patent number: 9371390
    Abstract: The disclosure relates to methods and compositions effective in the diagnosis, prognosis and treatment of human hematopoietic cancers. In particular, the disclosure provides tumor-associated genes that encode for cytokine receptors that are differentially expressed in hematopoietic tumor cells of myeloid origin compared with other cells, e.g., normal stem cells.
    Type: Grant
    Filed: April 3, 2014
    Date of Patent: June 21, 2016
    Assignee: Cellerant Therapeutics, Inc.
    Inventor: Holger Karsunky
  • Antibodies specific for CLL-1
    Patent number: 9163090
    Abstract: Provided herein are antibodies specific for CLL-1.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: October 20, 2015
    Assignee: Cellerant Therapeutics, Inc.
    Inventors: Ping Jiang, Holger Karsunky, Rob Tressler
  • CYTOKINE RECEPTORS ASSOCIATED WITH MYELOGENOUS HAEMATOLOGICAL PROLIFERATIVE DISORDERS AND USES THEREOF
    Publication number: 20140335103
    Abstract: The disclosure relates to methods and compositions effective in the diagnosis, prognosis and treatment of human hematopoietic cancers. In particular, the disclosure provides tumor-associated genes that encode for cytokine receptors that are differentially expressed in hematopoietic tumor cells of myeloid origin compared with other cells, e.g., normal stem cells.
    Type: Application
    Filed: April 3, 2014
    Publication date: November 13, 2014
    Applicant: Cellerant Therapeutics, Inc.
    Inventor: Holger Karsunky
  • Methods of expanding myeloid cell populations and uses thereof
    Patent number: 8877495
    Abstract: The present disclosure relates to a method of expanding myeloid progenitor cells by culturing an initial population of cells in a medium comprising a mixture of cytokines and growth factors that promote growth and expansion of the myeloid progenitor cells. The expanded cell population provides a source of cells as therapeutic treatments for neutropenia and/or thrombocytopenia arising in patients subjected to myeloablative therapy and hematopoietic stem cell transplantation.
    Type: Grant
    Filed: July 2, 2012
    Date of Patent: November 4, 2014
    Assignee: Cellerant Therapeutics, Inc.
    Inventors: Timothy C. Fong, Adrianus Geertrudis Wilhelmus Domen, Julie Lynne Christensen
  • Antibodies that specifically bind to TIM3
    Patent number: 8841418
    Abstract: Provided herein are antibodies specific for TIM3 that can be used to detect cancer cells, in particular, cancer stem cells. The antibodies can also be used in therapeutic compositions for treating cancer and reducing inflammation.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: September 23, 2014
    Assignee: Cellerant Therapeutics, Inc.
    Inventors: Holger Karsunky, Ying-Ping Jiang
  • MEGAKARYOCYTE PROGENITOR CELLS FOR PRODUCTION OF PLATELETS
    Publication number: 20140205582
    Abstract: Provided herein are methods of generating megakaryocyte lineage cells from hematopoietic stem cells in the absence of feeder cells and serum. The megakaryocyte progenitor cells (MKPs) generated as described result in rapid production of significant numbers of platelets when administered in vivo.
    Type: Application
    Filed: July 6, 2012
    Publication date: July 24, 2014
    Applicant: CELLERANT THERAPEUTICS, INC.
    Inventors: Holger Karsunky, Chanawan Chanaukul, Swapna Pantuganti
  • Compositions and methods for treating haematological proliferative disorders of myeloid origin
    Patent number: 8715619
    Abstract: The disclosure relates to methods and compositions effective in the diagnosis, prognosis and treatment of human hematopoietic cancers. In particular, the disclosure provides tumor-associated genes that encode for cytokine receptors that are differentially expressed in hematopoietic tumor cells of myeloid origin compared with other cells, e.g., normal stem cells.
    Type: Grant
    Filed: February 11, 2013
    Date of Patent: May 6, 2014
    Assignee: Cellerant Therapeutics, Inc.
    Inventor: Holger Karsunky